-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

802.P1.30 802. Chemical Biology and Experimental Therapeutics: Poster I

Chemical Biology and Experimental Therapeutics Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 5, 2015: 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Somayeh Samadzadeh Tarighat, PhD1, Fei Fei1*, Khuchtumur Bum-Erdene2*, Helen Blanchard2*, John Groffen1* and Nora Heisterkamp, PhD1*

1Division of Hematology/Oncology and Bone Marrow Transplant, Children's Hospital Los Angeles, Los Angeles, CA
2Institute for Glycomics, Griffith University, Gold Coast Campus, Queensland, Australia

Alice Pecoraro*, Antonio Troia*, Angela Vitrano*, Rosario Di Maggio*, Massimiliano Sacco*, Aurelio Maggio and Rosalba Di Marzo*

Campus of Haematology Franco e Piera Cutino- A.O.O.R. “Villa Sofia-Cervello”, Palermo, Italy

Jiusheng Deng, PhD1*, Dongkyoo Park, PhD2*, Mengchang Wang3*, Qiaoya Deng2*, Shannon Matulis, PhD4*, Lawrence H. Boise, PhD5 and Xingming Deng, MD, PhD6*

1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
2Emory Winship Cancer Institute, Atlanta
3The First Affiliated Hospital, Xi’An Jiaotong University, Xi'An, China
4Hematology and Medical Oncology, Emory University, Atlanta, GA
5Hematology & Medical Oncology, Emory University, Atlanta, GA
6Emory University Winship Cancer Institute, Atlanta, GA

Jing Lu, Ph.D.1*, Yimin Qian, Ph.D.1*, Kanak Raina, PhD1*, Martha Altieri, MS1*, Hanqing Dong, PhD1*, Jing Wang, PhD1*, Xin Chen, PhD1*, Andrew Crew, PhD1*, Kevin Coleman, PhD1*, Craig Crews, PhD2* and James Winkler, PhD1

1Arvinas, LLC, New Haven, CT
2Department of Molecular, Cellular, and Developmental Biology, Department of Chemistry, Department of Pharmacology, yale university, New Haven, CT

Jo Ishizawa, MD, PhD1*, Kensuke Kojima, MD, PhD1,2*, Dhruv Chachad, MS3*, Peter Ruvolo, PhD3, Vivian Ruvolo, MS4*, Rodrigo Omar Jacamo, PhD3*, Gautam Borthakur, MD5, Hong Mu, MD, PhD6*, Zhihong Zeng, MD4, Yoko Tabe, MD, PhD1, Joshua Allen, Ph.D.7*, Zhiqiang Wang, PhD8*, Wencai Ma, PhD9*, Hans Lee, MD10*, Robert Z. Orlowski, Ph.D., M.D.9, Dos D. Sarbassov, PhD11*, Sattva S. Neelapu, MD12, Timothy J. McDonnell, MD, PhD13, Roberto N. Miranda, MD14, Michael Wang, MD12, Hagop M Kantarjian, MD5, Marina Konopleva, MD, PhD1, Richard Eric Davis, M.D.8* and Michael Andreeff, M.D., Ph.D.1

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
2Hematology, Respiratory Medicine and Oncology, Department of Medicine, Saga University, Saga, Japan
3Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Section of Molecular Hematology and Therapy, Leukemia Department, UT MD Anderson Cancer Center, Houston, TX
7Oncoceutics, Inc, Hummelstown, PA
8Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston
9Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
10Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX
11Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston
12Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
13Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston
14Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Pritesh R. Patel, MB, ChB1, Vitalyi Senyuk, PhD1, Dolores Mahmud, PhD1*, Annie L. Oh, MD1 and Damiano Rondelli, MD2

1Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL
2Section of Hematology/Oncology, Dept. of Medicine, University of Illinois at Chicago, Chicago

David T Tran, PhD1, Max J Petersen1*, Charles O Noble, PhD1*, Mark E Hayes, PhD1*, Peter Working, PhD1* and Francis C Szoka, PhD1,2*

1ZoneOne Pharma, Inc., San Francisco, CA
2Dept. of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA

Tomohiro Kozako, PhD1, Makoto Yoshimitsu, MD, PhD2, Naomichi Arima, MD, PhD3, Shuhei Soeda, PhD1*, Shinya Hirata, MD, PhD4*, Hiroaki Tanaka, PhD5*, Shin-ichiro Honda, PhD1* and Shinji Soeda, PhD1*

1Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
2Hem. and Immunology, Kagoshima University Hosp., Kagoshima, Japan
3Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan
4Department of Hematology, Kumamoto University Graduate School of Medicine, Kumamoto, Japan
5Faculty of Sports and Health Science, Fukuoka University, Fukuoka, Japan

Lata Chauhan, PhD*, Emilie J Bergsma* and Jatinder K Lamba, Ph.D

Department of Pharmacotherapy and Translational Research College of Pharmacy, University of Florida, Gainesville, FL

*signifies non-member of ASH